口咽益生菌DSM 34540辅助治疗儿童急性上呼吸道感染和预防继发细菌感染的临床功效及机制

注册号:

Registration number:

ChiCTR2300071252 

最近更新日期:

Date of Last Refreshed on:

2023-06-06 21:21:56 

注册时间:

Date of Registration:

2023-05-09 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

口咽益生菌DSM 34540辅助治疗儿童急性上呼吸道感染和预防继发细菌感染的临床功效及机制

Public title:

Clinical efficacy and mechanism of oropharyngeal probiotic DSM 34540 in the adjuvant treatment of acute upper respiratory tract infections and prevention of secondary bacterial infections in children

注册题目简写:

English Acronym:

研究课题的正式科学名称:

口咽益生菌DSM 34540辅助治疗儿童急性上呼吸道感染和预防继发细菌感染的临床功效及机制

Scientific title:

Clinical efficacy and mechanism of oropharyngeal probiotic DSM 34540 in the adjuvant treatment of acute upper respiratory tract infections and prevention of secondary bacterial infections in children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

何明心 

研究负责人:

王强 

Applicant:

He Mingxin 

Study leader:

Wang Qiang 

申请注册联系人电话:

Applicant telephone:

+86 135 9461 1824

研究负责人电话:

Study leader's
telephone:

+86 159 7150 9779

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

mingxin_he2021@163.com

研究负责人电子邮件:

Study leader's E-mail:

wangqiang@wust.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

湖北省武汉市洪山区黄家湖西路2号

研究负责人通讯地址:

湖北省武汉市洪山区黄家湖西路2号

Applicant address:

2 Huangjiahu Road West, Hongshan District, Wuhan, Hubei

Study leader's address:

2 Huangjiahu Road West, Hongshan District, Wuhan, Hubei

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

武汉科技大学医学院

Applicant's institution:

School of Medicine, Wuhan University of Science and Technology

研究负责人所在单位:

武汉科技大学医学院

Affiliation of the Leader:

School of Medicine, Wuhan University of Science and Technology

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

WAGHMEC-KT-2022007;202214

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

武汉亚心总医院医学伦理委员会;武汉科技大学医学院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of Wuhan Yashin General Hospital; Medical Ethics Committee of Wuhan University of Science and Technology School of Medicine

伦理委员会批准日期:

Date of approved by ethic committee:

2022-06-21 00:00:00

伦理委员会联系人:

王佳敏

Contact Name of the ethic committee:

Wang Jiamin

伦理委员会联系地址:

湖北省武汉市汉阳区经济技术开发区太子湖北路300号

Contact Address of the ethic committee:

300 Taizihu Road North, Economic and Technological Development Zone, Hanyang District, Wuhan, Hubei

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 27 8478 8999

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

武汉科技大学医学院

Primary sponsor:

School of Medicine, Wuhan University of Science and Technology

研究实施负责(组长)单位地址:

湖北省武汉市洪山区黄家湖西路2号

Primary sponsor's address:

2 Huangjiahu Road West, Hongshan District, Wuhan, Hubei

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

湖北

市(区县):

武汉

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉科技大学医学院

具体地址:

洪山区黄家湖西路2号

Institution
hospital:

School of Medicine, Wuhan University of Science and Technology

Address:

2 Huangjiahu Road West, Hongshan District

经费或物资来源:

武汉亚心总医院科研创新基金重点项目 (2022KYCX1-A04)

Source(s) of funding:

Key Project of Research and Innovation Fund of Wuhan Yashin General Hospital (2022KYCX1-A04)

研究疾病:

急性上呼吸道感染  

Target disease:

Acute upper respiratory tract infection

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

评估有益于口咽菌群维持的口咽益生菌DSM 34540作为辅助治疗儿童急性上呼吸道感染和预防继发细菌感染的临床功效并探讨其作用机制。  

Objectives of Study:

To evaluate the clinical efficacy and mechanism of oral probiotics DSM 34540, which is beneficial to the maintenance of oropharyngeal flora, as an adjunct to the treatment of acute upper respiratory tract infection and the prevention of secondary bacterial infection in children.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.免疫功能低下或免疫缺陷。 2.已切除扁桃体。 3.有风湿性疾病的病史。 4.患有支气管痉挛和/或哮喘F和/或过敏性鼻炎。 5.对牛奶蛋白过敏。 6.患有呼吸系统疾病,系统性疾病如糖尿病、肾脏病、胃肠道疾病、慢性鼻窦炎。 7.患有麻疹、腮腺炎或风疹等传染病。 8.近7天内曾使用抗生素。 9.近30天内使用免疫抑制剂药物(包括口服或鼻用类固醇)。 10.在近14天内服用其他益生菌产品。

Exclusion criteria:

1. Immune dysfunction or deficiency. 2. The tonsils have been removed. 3. History of rheumatic diseases. 4. Have bronchospasm and/or asthma F and/or allergic rhinitis. 5. Allergic to cow's milk protein. 6. Patients with respiratory diseases, systemic diseases such as diabetes, kidney disease, gastrointestinal disease, chronic sinusitis. 7. Have an infectious disease such as measles, mumps or rubella. 8. Antibiotics have been used in the last 7 days. 9. Use of immunosuppressant drugs (including oral or nasal steroids) within the last 30 days. 10. Take other probiotic products within the last 14 days.

研究实施时间:

Study execute time:

From 2022-06-01 00:00:00 To 2024-06-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2023-06-01 00:00:00 To 2024-06-01 00:00:00

干预措施:

Interventions:

组别:

干预组

样本量:

100

Group:

Intervention group

Sample size:

干预措施:

进行正常的治疗的前提下,施加益生菌干预。患儿每天早、中、晚孩子刷牙后,含服一片益生菌含片,在口腔中慢慢溶解,共7天。

干预措施代码:

Intervention:

Under the premise of normal treatment, probiotic intervention was applied. After brushing their teeth every morning, noon and evening, the children took a probiotic buccal tablet and slowly dissolved it in the mouth for 7 days.

Intervention code:

组别:

对照组

样本量:

100

Group:

Control group

Sample size:

干预措施:

进行正常的治疗,不施加益生菌干预。

干预措施代码:

Intervention:

Perform normal treatment without probiotic intervention.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

湖北 

市(区县):

武汉 

Country:

China

Province:

Hubei

City:

Wuhan

单位(医院):

武汉亚心总医院 

单位级别:

三级 

Institution
hospital:

Wuhan Yashin General Hospital

Level of the institution:

Tertiary

测量指标:

Outcomes:

指标中文名:

唾液中的细胞因子

指标类型:

主要指标

Outcome:

Cytokines in saliva

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

唾液中的菌群

指标类型:

主要指标

Outcome:

Flora in saliva

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

唾液中的代谢物

指标类型:

主要指标

Outcome:

Metabolites in saliva

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 5 years
最大 Max age 12 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

研究者使用SPSS 26.0 软件进行随机化

Randomization Procedure (please state who generates the random number sequence and by what method):

The researchers used SPSS 26.0 software for randomization.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

不公开/Private

盲法:

患儿按此随机分组表顺序随机入组

Blinding:

Children were randomized according to the order of this randomized grouping table

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

是否可以不共享原始数据呢

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Is it possible to not share raw data?

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

是否可以不共享原始数据呢

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Is it possible to not share raw data?

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2023-05-09 15:45:15